Double-barreled CAR-T takes aim at hard-to-treat blood cancers
NCT ID NCT06986434
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This early-phase study tests a new type of immunotherapy called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms, lymphomas, or leukemias) that have relapsed or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on cancer cells. The main goals are to check safety and find the best dose, with 20 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.